The NovoTTF-100L System

For the first time in over 15 years,
there's an FDA-approved treatment
for mesothelioma

NovoTTF-100L + chemotherapy is approved to
treat people with unresectable, locally advanced
or metastatic, malignant pleural mesothelioma

The majority of people who used NovoTTF-100L + chemotherapy saw their mesothelioma shrink or stop growing

  • The only side effect of NovoTTF-100L was skin irritation seen in 71% of patients (66% mild to moderate and 5% severe)
Learn more about study results for NovoTTF-100L™ + chemo

A clinical study showed using NovoTTF-100L + chemotherapy helped people with mesothelioma live longer

See the clinical data
24/7 support for you and your caregiver

24/7 support for you and your caregiver

Learn more about nCompass™
Downloadable Skin Care Guidelines, Understanding the NovoTTF-100L™ System, and nCompass™ support brochure

you can download

Download here
Learn about the number of patients who have been treated with TTFields to date

More than 10,000 people globally have started a cancer treatment that works the same way as NovoTTF-100L. It is called Optune® and has been used since 2011 to treat a type of brain cancer called glioblastoma, also known as GBM.

The FDA first approved Optune to treat recurrent GBM in 2011, and newly diagnosed GBM in 2015.

NovoTTF-100L for MPM is classified as a Humanitarian Use Device (HUD), approved under the Humanitarian Device Exemption (HDE) pathway.

Optune was approved under the Premarket Approval (PMA) Pathway.

Caution: Federal law restricts this device to sale by or on the order of a physician. Humanitarian Device. Authorized by Federal Law for use in the treatment of adult patients with unresectable, locally advanced or metastatic, malignant pleural mesothelioma concurrently with pemetrexed and platinum-based chemotherapy. The effectiveness of this device for this use has not been demonstrated.

Device carrying bag for everyday life

References: 1. NovoTTF-100L Instructions For Use for Unresectable Malignant Pleural Mesothelioma. Novocure 2019. 2. FDA Approves the NovoTTF-100L™ System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma [press release]. St. Helier, Jersey: Business Wire; May 23, 2019. 3. Hazarika M, White RM, Johnson JR, et al. FDA drug approval summaries: pemetrexed (Alimta®). The Oncologist. 2004;9(5):482-488. 4. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636-2644. 5. NovoTTF-100L Patient Information and Prescribing Manual. Novocure 2019. 6. Summary of Safety and Effectiveness Data (SSED). US FDA Website. Accessed April 9, 2019.

Next: Disease overview
Back to top
What is the NovoTTF-100L™ System approved to treat?
jump to isi

The NovoTTF-100L System is a wearable, portable, FDA-approved device indicated for…